Clinical Trials Browser

Phase 2/3 × Recruiting × Gynecologic × Clear all

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Phase 2/3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Phase 2/3 Recruiting

Uterine Cervical Neoplasms

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

Endometrial Neoplasms

NCT06161025 2026-01-12

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07298642 2025-12-23

Extended-field Proton Therapy for Cervical Cancer

Phase 2/3 Recruiting

Uterine Cervical Neoplasms

NCT03651206 2025-12-19

ROCSAN

Phase 2/3 Recruiting

GynecologicSarcoma

Ovarian Carcinosarcoma

NCT05381597 2025-11-28

5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer

Phase 2/3 Recruiting

Squamous Intraepithelial Lesions

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT05316467 2025-08-11

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

Phase 2/3 Recruiting

GynecologicOther

Infertility, Obesity, Endometrial Neoplasms, Overweight

NCT06791460 2025-03-18

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

Phase 2/3 Recruiting

Ovarian Cancer Recurrent

NCT05255653 2024-11-29

RAINBO

Phase 2/3 Recruiting

Endometrial Neoplasms

NCT06288373 2024-10-30

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Phase 2/3 Recruiting

Uterine Cervical Neoplasms

NCT05797831 2024-05-02

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Phase 2/3 Recruiting

Endometrial Neoplasms

NCT06341907 2024-04-02

Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC

Phase 2/3 Recruiting

Carcinoma, Ovarian Epithelial

NCT03458221 2023-04-18

STAPOVER

Phase 2/3 Recruiting

Ovarian Neoplasms, Neoplasms, Second Primary